#5: Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS,
INC. (Nasdaq: VION) today announced that data from a previously conducted
Phase II...
#3: Vion Pharmaceuticals Presents Preliminary Data from its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at ASH Annual Meeting
NEW HAVEN, Conn., Dec. 10 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that data from its pivotal Phase II trial of its lead anticancer agent...
#2: Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
Company to Hold Conference Call on Monday, December 10, 2007
NEW HAVEN, Conn., Dec. 6 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals,
Inc. (Nasdaq: VION) today announced that...
Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly Patients with De Novo Poor-Risk AML Continues to Accrue Patients
Company to Hold Conference Call at 10:30 A.M. Eastern Time Today
VION...